Literature DB >> 30737159

Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis.

Takehiro Iwata1, Shoji Kimura2, Beat Foerster3, Mohammad Abufaraj4, Pierre I Karakiewicz5, Felix Preisser6, Yasutomo Nasu7, Shahrokh F Shariat8.   

Abstract

AIM: To investigate the association of perioperative blood transfusion (PBT) with oncologic outcomes in patients with renal cell carcinoma (RCC), we conducted a systematic review and meta-analysis of the literature to clarify the long-term oncologic effect of PBT in patients undergoing nephrectomy for RCC.
MATERIALS AND METHODS: We searched the MEDLINE, Web of Science, Cochrane Library and Scopus on 15th April 2018 to identify studies that compared patients who received PBT undergoing radical or partial nephrectomy for RCC to patients who did not with the aim of evaluating its impact on overall mortality (OM), cancer-specific mortality (CSM) and disease recurrence using multivariable cox regression analysis.
RESULTS: A total of 19,681 patients in 7 studies matched the selection criteria for the systematic review and meta-analysis. All 7 studies were retrospective design and published between 1994 and 2018. Our study included low quality of eligible studies due to their retrospective design and showed a significant heterogeneity. PBT was associated with OM (pooled hazard ratio [HR], 1.49, 1.24-1.78), CSM (pooled HR, 1.46, 1.20-1.77), and disease recurrence (pooled HR, 1.80, 1.03-3.12). In a subgroup analysis of 3,664 patients with nonmetastatic RCC, PBT was remained associated with OM (pooled HR, 1.91; 1.06-3.41), but not anymore with CSM (pooled HR, 1.92, 0.94-3.91) or disease recurrence (pooled HR, 2.18, 0.86-5.55).
CONCLUSIONS: PBT in patients undergoing nephrectomy for RCC is associated with worse overall survival. While PBT may be reflective of the underlying aggressiveness of the disease, it could be that its detrimental effect on outcomes is caused by its negative effect on the host's resilience.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood transfusion; Clinical outcomes; Renal cell carcinoma; Surgery

Mesh:

Year:  2019        PMID: 30737159     DOI: 10.1016/j.urolonc.2019.01.018

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  3 in total

1.  Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system.

Authors:  Ryan Sun; Rodney H Breau; Ranjeeta Mallick; Simon Tanguay; Frederic Pouliot; Anil Kapoor; Luke T Lavallée; Antonio Finelli; Alan I So; Ricardo A Rendon; Adrian S Fairey; Jean-Baptiste Lattouf; Jun Kawakami; Bimal Bhindi; Naveen S Basappa; Lori A Wood; Georg A Bjarnason; Daniel Y C Heng; Rahul K Bansal
Journal:  Can Urol Assoc J       Date:  2021-04       Impact factor: 1.862

2.  Impact of perioperative blood transfusion on oncologic outcomes in patients with nonmetastatic renal cell carcinoma treated with curative nephrectomy: A retrospective analysis of a large, single-institutional cohort.

Authors:  Dong Young Seon; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku; Hyung Suk Kim
Journal:  Investig Clin Urol       Date:  2020-02-17

3.  Frailty predicts outcome of partial nephrectomy and guides treatment decision towards active surveillance and tumor ablation.

Authors:  M T Walach; M F Wunderle; N Haertel; J K Mühlbauer; K F Kowalewski; N Wagener; N Rathmann; M C Kriegmair
Journal:  World J Urol       Date:  2021-01-30       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.